□ 本报记者詹超 8月5日，央行等七部门联合印发《关于金融支持新型工业化的指导意见》，为金融活水精准浇灌新型工 业化指明方向。 作为工业大省，江苏持续创新金融服务方式，通过把"看得见的抵押"换成"算得出的成长"，把"银行柜 台"搬进实验室，把"产业链"接上"资本链"，让金融活水先一步流进车间、研发线和订单簿，构建起金 融赋能新型工业化的立体生态。 "积分尺"量准信用，巧解融资难题 面对众多科技企业"轻资产难估值、好项目缺资金"的融资堵点，2024年，江苏率先在全国亮出"苏创积 分贷"这把利剑。它从重点产业领域、创新投入能力、创新管理能力、创新产出能力、成长经营能力及 辅助加分项六大维度入手，将研发费用占比、专利数量、技术合同成交额、科技奖励等24项指标，化作 精准衡量企业创新力的标尺，把企业清晰划分为"优先支持、推荐支持、一般支持、培育支持"四类，为 银行送上一份看得见、摸得着的"科技画像"。 "银行主动找上门，500万元贷款两天就批下来了！"南京智达自动化集团董事长魏乙提起"苏创积分 贷"，语气里满是感慨。这家深耕节能环保设备研发的企业，当时正处在关键冲刺期：新产品排着队要 上市，新一代智慧环保平台亟待上线 ...

Core Viewpoint - Zhejiang Yaguang Technology Co., Ltd. reported significant declines in revenue and net profit for 2024, with revenue at 801 million yuan and net profit at 102 million yuan, representing year-on-year decreases of 17.80% and 36.79% respectively. Despite an increase in overall gross margin to 34.29%, the performance varied across business segments, with the pharmaceutical machinery segment experiencing a gross margin decline of 5.97% to 29.57% while the energy-saving and environmental protection segment saw an increase of 2.91% to 35.60% [1][10][11]. Business Performance - The company operates primarily in pharmaceutical machinery and energy-saving environmental equipment, with a notable decline in demand attributed to reduced investment in the pharmaceutical sector and ongoing procurement policies [10][11]. - The top five customers in the pharmaceutical machinery segment reported a total transaction amount of 65.73 million yuan, down 25.01% year-on-year, while the energy-saving segment's top five customers had transactions totaling 395.14 million yuan, a decrease of 8.77% [10][11]. Customer and Supplier Relationships - The company is required to disclose detailed information about its top five customers and suppliers, including transaction amounts, pricing basis, and payment terms, to provide transparency regarding its business operations [2][12]. - The company has a diverse customer base with varying procurement plans based on fixed asset investment and project progress, leading to fluctuations in sales revenue [10][11]. Cost Structure and Pricing - The cost structure of the company's business segments is influenced by the customized nature of its products, which are tailored to meet specific customer requirements, resulting in significant variations in manufacturing costs and pricing strategies [11][15]. - The pricing of products is based on manufacturing costs, customer procurement scale, and competitive factors, leading to differences in sales prices among various customers [11][15]. Financial Metrics - The gross margin for the pharmaceutical machinery segment decreased to 29.57%, while the energy-saving segment improved to 35.60%, indicating differing performance across the segments [1][10]. - Accounts receivable and contract liabilities for the top five customers in the pharmaceutical machinery segment showed a decline of 29.10% and 26.80% respectively, reflecting the overall decrease in revenue [12][15].

Core Viewpoint - Zhejiang Yaguang Technology Co., Ltd. reported significant declines in revenue and net profit for 2024, with revenue at 801 million yuan and net profit at 102 million yuan, representing year-on-year decreases of 17.80% and 36.79% respectively. Despite an increase in gross margin to 34.29%, the performance varied across business segments, with the pharmaceutical machinery segment experiencing a gross margin drop of 5.97% to 29.57% [1][9]. Group 1: Business Performance - The company operates in pharmaceutical machinery and energy-saving environmental equipment, with a notable decline in revenue and profit for 2024 [1]. - The gross margin for the pharmaceutical machinery segment decreased to 29.57%, while the energy-saving segment saw an increase to 35.60% [1][9]. - The top five customers in the pharmaceutical machinery segment reported a total transaction amount of 659.73 million yuan, reflecting a year-on-year decrease of 25.01% due to reduced investment in the pharmaceutical sector and ongoing procurement policies [9][10]. Group 2: Customer and Supplier Relationships - The company is required to disclose detailed information about its top five customers and suppliers, including transaction amounts, pricing basis, and settlement terms [2]. - The pharmaceutical machinery segment's top five customers had accounts receivable totaling 157.31 million yuan, a decrease of 29.10% year-on-year [11]. - The energy-saving segment's top five customers reported transaction amounts of 395.14 million yuan, down 8.77% year-on-year, influenced by falling lithium salt prices and overcapacity [9][10]. Group 3: Market Dynamics - The company's sales revenue is closely tied to customer capital expenditure plans and project progress, leading to fluctuations in procurement patterns [9]. - The company’s products are customized to meet specific technical requirements, which affects manufacturing costs and pricing strategies [10]. - The pricing strategy considers various factors, including customer procurement scale, cooperation duration, and competitive landscape, resulting in price variations among different customers [10].